Related Experiment Video

Updated: Aug 23, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

DPP3: From biomarker to therapeutic target of cardiovascular diseases

Peng Ye1, Wei Duan1,2, Yue-Qi Leng1

  • 1Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China.

Frontiers in Cardiovascular Medicine
|October 31, 2022
PubMed

Insights

Dipeptidyl peptidase 3 (DPP3) is linked to cardiovascular disease mortality and blood pressure regulation. Further research into DPP3

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Research
  • Enzymology

Background:

  • Cardiovascular diseases (CVDs) are the leading global cause of death, presenting a significant socioeconomic burden.
  • Dipeptidyl peptidase 3 (DPP3), a zinc-dependent peptidase with a HEXXGH catalytic motif, degrades oligopeptides.
  • DPP3 is implicated in various cellular activities and pathophysiological mechanisms, including cardiovascular disease.

Purpose of the Study:

  • To review recent advances in the structure, catalytic activity, and biological functions of DPP3.
  • To explore the role of DPP3 as a potential therapeutic target in cardiovascular diseases.
  • To provide a theoretical basis for understanding DPP3's involvement in cardiovascular health and disease.

Main Methods:

  • Literature review of existing research on DPP3 structure, function, and its role in cardiovascular diseases.
  • Analysis of current evidence linking DPP3 to disease prognosis, blood pressure regulation, inflammation, and oxidative stress.
  • Synthesis of findings to evaluate DPP3's potential as a therapeutic target.

Main Results:

  • DPP3 is a biomarker for poor prognosis in cardiovascular diseases like cardiogenic shock and heart failure.
  • Emerging evidence suggests DPP3 regulates blood pressure via interaction with the renin-angiotensin system.
  • DPP3 is involved in pain signaling, inflammation, and oxidative stress, processes relevant to cardiovascular function.

Conclusions:

  • DPP3 plays a multifaceted role in cardiovascular pathophysiology, extending beyond its biomarker status.
  • Understanding the precise mechanisms of DPP3 in cardiovascular function is crucial for therapeutic development.
  • DPP3 represents a promising, yet underexplored, therapeutic target for cardiovascular diseases.

Keywords:
biomarkercardiovascular diseasesdipeptidyl peptidase 3renin-angiotensin systemtherapeutic target

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

263
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
164
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
233
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
262
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19